Zanidatamab + Chemotherapy as First-line Treatment for Metastatic Gastric Adenocarcinoma (mGEA)

Elena Elmia, MD, MSC,1 Jaffer Ajani, MD,2 Howard Burris, MD,3 Crystal S. Denlinger, MD,4 Yoon-Koo Kang, MD,5 Phu,6 Yeu Hoon Kim, MD, PhD,7 Keun-Week Lee, MD, PhD,2 Bruce Lin, MD,8 Rutika Mehta, MD, MPH,9 Do-Young Oh, MD, PhD10

1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2National Cancer Institute, Bethesda, MD, USA; 3University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Vanderbilt University Medical Center, Nashville, TN, USA; 5Astellas Pharma USA, Inc., Northbrook, IL, USA; 6Samsung Medical Center, Seoul, South Korea; 7Asan Medical Center, Seoul, South Korea; 8Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA; 9National University Hospital, Singapore, Singapore; 10Kyu-hyung Kang, MD, PhD, Department of Gastrointestinal Medical Oncology, National Cancer Center, Goyang, South Korea

Background and Methods

• Zanidatamab has demonstrated clinical activity (ORR 34%) at 3 mg/kg in the neoadjuvant setting for first-line treatment of HER2+ gastroesophageal adenocarcinoma.

• Zanidatamab + chemotherapy is highly active treatment regimen for first-line treatment of patients with HER2+ mGEA.

• This maturing data set demonstrates durable disease control with encouraging median duration of response (10.4 months).

• Zanidatamab combined with standard chemotherapy is a highly active treatment regimen for first-line treatment of patients with HER2+ mGEA.

Efficacy

Table 2: Progression-Free Survival in Patients with HER2-positive mGEA

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Median PFS (mo) (95% CI)</th>
<th>ORR (%)</th>
<th>cCR (%)</th>
<th>Disease Control Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanidatamab + mFOLFOX6</td>
<td>11 (5, 17)</td>
<td>39</td>
<td>9</td>
<td>99</td>
</tr>
<tr>
<td>CAPOX</td>
<td>8.3 (2.6, NE)</td>
<td>11</td>
<td>0</td>
<td>11</td>
</tr>
</tbody>
</table>

Table 3: Summary of Baseline Characteristics Among Chemotherapy Regimens

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Zanidatamab + mFOLFOX6</th>
<th>CAPOX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>61 (57, 67)</td>
<td>62 (58, 79)</td>
</tr>
<tr>
<td>ECOG Performance Status, n (%)</td>
<td>0/1: 30/70</td>
<td>25/75</td>
</tr>
<tr>
<td>CA = primary tumor type; E = esophageal cancer; F = flat dosing regimen; FISH = fluorescence in situ hybridization; G = gastric cancer; IHC = immunohistochemistry; J = gastroesophageal junction</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results

• Zanidatamab + chemotherapy is highly active treatment regimen for first-line treatment of patients with HER2+ mGEA.

• This maturing data set demonstrates durable disease control with encouraging median duration of response (10.4 months).

• This maturing data set demonstrates durable disease control with encouraging median duration of response (10.4 months).

Conclusions

• Zanidatamab combined with standard chemotherapy is a highly active treatment regimen for first-line treatment of patients with HER2+ mGEA.

• This maturing data set demonstrates durable disease control with encouraging median duration of response (10.4 months).

• Zanidatamab + chemotherapy is highly active treatment regimen for first-line treatment of patients with HER2+ mGEA.

• This maturing data set demonstrates durable disease control with encouraging median duration of response (10.4 months).

References and Acknowledgments

[Please provide a list of references and acknowledgment details here.]

Note: All patients are being followed on study treatment until disease progression, death, or study closure. Dose delays or holds per protocol were allowed. TRAEs leading to treatment discontinuation or dose reductions were recorded. TRAEs leading to dose reductions were recorded. Patients received all study treatments through the first 25 patients treated.

Abstract: B 347

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]

[Please provide the authors' affiliations here.]

[Please provide the abstract details here.]